NanoMedSyn develops an innovative Enzyme Replacement Therapy (ERT) solution to find the best way to treat Lysosomal Storage Diseases.

This start-up company is engaged in glycochemistry, protein functionalization and drug delivery. Thanks to their expertise in glycochemistry and drug delivery, NanoMedSyn’s founders have built a new technical approach to respond to the unmet medical needs of Lysosomal Storage Disorders. They patented a library of synthetic derivatives called AMFA, designed for the targeting of a specific membrane lectin, the mannose 6-phosphate receptor, the major addressing pathway to lysosomes. These AMFA compounds when linked to some molecules have the potential to target them to tissues and cells overexpressing these RM6P, to facilitate their cellular uptake and finally to address them to lysosomes.

The main application is the production of new modified recombinant enzymes for the treatment of lysosomal rare disorders. In Lysosomal Storage Disorders, the absence or dysfunction of one of the key lysosomal enzymes leads to the accumulation of the concerned substrate. Over the past few years, important efforts have been made to develop enzyme replacement therapy (ERT) to treat these diseases. However, only 7 of the 53 lysosomal storage disorders benefit of a treatment, and some of them can be improved.

Thanks to the chemical coupling of its patented AMFA compound to the therapeutic enzymes, NanoMedSyn develops an innovative Enzyme Replacement Therapy (ERT) solution in order to find the best way to reply to the unmet clinical needs of lysosomal storage diseases.

The new technology of NanoMedSyn can be applied to existing and also new recombinant enzymes developed for orphan lysosomal diseases.

With this platform, NanoMedSyn may also provide efficient solutions for targeting of cancer therapy.